retatrutide safety clinical trials profile The FDA has issued warning letters to multiple companies marketing compounded Trial of next-gen weight-loss drug

With multi-agonists like Tirzepatide and Retatrutide on the horizon (triple agonist showing promise in trials), adoption will soar

In Chronic Kidney Disease, they decrease albuminuria and eGFR decline

While this result was widely expected, it does define a new era of competitiveness and serves as a harbinger of things to come in a market that will become much more crowded, as numerous competitors are lining up to claim their share of the obesity opportunity

My doctor also said she doesnt really get the idea of microdosing, seeing no reason I wouldnt try the typical course

doi: 10.1007/s001040051225 57 BreederveldRSTuinebreijerWE